Acrivon Therapeutics
ACRV
ACRV
40 hedge funds and large institutions have $196M invested in Acrivon Therapeutics in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.44% less ownership
Funds ownership: 69.42% → 68.98% (-0.44%)
Holders
40
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$1.3M | |
| 2 | +$766K | |
| 3 | +$527K | |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$333K |
| 5 |
Nuveen Asset Management
Chicago,
Illinois
|
+$153K |
Top Sellers
| 1 | -$4.01M | |
| 2 | -$409K | |
| 3 | -$194K | |
| 4 |
Goldman Sachs
New York
|
-$174K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$77K |